Skip to main content
Log in

What Do Randomized Controlled Trials Inform Us About Potential Disease-Modifying Strategies for Parkinson’s Disease?

  • Review
  • Published:
NeuroMolecular Medicine Aims and scope Submit manuscript

Abstract

Research advances have shed new insight into cellular pathways contributing to PD pathogenesis and offer increasingly compelling therapeutic targets. In this review, we made a broad survey of the published literature that report possible disease-modifying effects on PD. While there are many studies that demonstrate benefits for various therapies for PD in animal and human studies, we confined our search to human “randomised controlled trials” and with the key words “neuroprotection” or “disease-modifying”. It is hoped that through studying the results of these trials, we might clarify possible mechanisms that underlie idiopathic PD. This contrasts with studying the effect of pathophysiology of familial PD, which could be carried out by gene knockouts and animal models. Randomised controlled trials indicate promising effects of MAO-B inhibitors, dopamine agonists, NMDA receptor antagonists, metabotropic glutamate receptor antagonists, therapies related to improving glucose utilization and energy production, therapies related to reduction of excitotoxicity and oxidative stress, statin use, therapies related to iron chelation, therapies related to the use of phytochemicals, and therapies related to physical exercise and brain reward pathway on slowing PD progression. Cumulatively, these approaches fall into two categories: direct enhancement of dopaminergic signalling, and reduction of neurodegeneration. Overlaps between the two categories result in challenges in distinguishing between symptomatic versus disease-modifying effects with current clinical trial designs. Nevertheless, a broad-based approach allows us to consider all possible therapeutic avenues which may be neuroprotective. While the traditional standard of care focuses on symptomatic management with dopaminergic drugs, more recent approaches suggest ways to preserve dopaminergic neurons by attenuating excitotoxicity and oxidative stress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

Download references

Acknowledgements

This work was supported by grants from the Ministry of Education (NUHSRO/2019/051/T1/Seed-Mar/04) and the National Medical Research Council of Singapore (HLCA21Jan-0019) and A*STAR Singapore.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wei-Yi Ong.

Ethics declarations

Conflict of interest

The authors have no conflict of interests to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ong, WY., Leow, D.MK., Herr, D.R. et al. What Do Randomized Controlled Trials Inform Us About Potential Disease-Modifying Strategies for Parkinson’s Disease?. Neuromol Med 25, 1–13 (2023). https://doi.org/10.1007/s12017-022-08718-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12017-022-08718-x

Keywords

Navigation